Objective To explore the relevances of serum prolactin level to clinical symptoms and disease activities of systemic lupus erythematosis (SLE). Methods From December 2008 to December 2014, 63 female patients who met the American Rheumatism Society diagnostic criteria of SLE in the First People’s Hospital of Chengdu were collected as the SLE group, and other 20 healthy females were collected as the control group. The serum prolactin level was determined by immunofluorescence, and the disease activity of SLE was assessed by SLE Disease Activity Index (SLEDAI). The relevances of serum prolactin level to clinical symptoms and disease activity of SLE patients were analyzed. Results The mean serum prolactin level was (22.35±14.86) ng/mL in the SLE group and (15.30±8.54) ng/mL in the control group, respectively; the difference was statistically significant (P<0.05). In the 63 SLE patients, 15 (23.8%) had higher serum prolactin level compared with the normal ones. According to the SLEDAI score, the SLE patients were divided into stable group (25 patients), mild activity group (21 patients), moderate activity group (10 patients), and severe activity group (7 patients); and their serum prolactin levels were (20.43±11.23), (22.50±13.54), (27.97±21.20), and (33.91±18.18) ng/mL, respectively; the differences were not statistically significant (P>0.05). There were statistically significant differences (P<0.05) between the SLE patients with hyperprolactinemia and the ones with normal serum prolactin level in a number of clinical symptoms such as serositis, kidney damage,hematological system damage, and hypocomplementemia, but the serum prolactin level was not significantly correlated with the SLEDAI (rs=0.217, P=0.088). Conclusions Less hyperprolactinemia is found in SLE patients. Serum prolactin level is correlated with multiple clinical symptoms and laboratory indexes but not related to disease activity in SLE patients.
Objective To summarize results of the correlation of tumor necrosis factor-α (TNF-α) promoter –308A/G polymorphism with systemic lupus erythematosus (SLE) susceptibility in Chinese populations. Methods We collected all the publications about the correlation between TNF-α promoter –308A/G polymorphism and SLE in Chinese populations by searching PubMed, EBSCO, CBM, CNKI and Wanfang Data before the date of March 20, 2010. Meta-analysis was performed for checking the difference between two groups about genotypes such as AA versus GG, GA versus GG, AA versus GG+GA, GA+AA versus GG, and A allele versus G allele. Results A total of 8 studies involving 731 SLE patients and 901 healthy people were included. The meta-analysis of total populations showed that, there was no significant correlation between A allele and increased SLE risk (OR=1.42, 95%CI 0.97 to 2.09, P=0.07); the meta-analyses of populations in different regions showed there was no significant correlation of A allele and increased SLE risk in Chinese Taiwan populations (OR=1.04, 95%CI 0.77 to 1.40, P=0.82). Moreover, there was no significant difference between SLE group and control group in the genotypes of AA versus GG, GA versus GG, AA versus GG+GA, and GA+AA versus GG.Conclusion This meta-analysis dosen’t demonstrate the correlation between TNF-α promoter–308A/G polymorphism and SLE in Chinese populations.
【摘要】 目的 检测B细胞成熟抗原(BCMA)mRNA在系统性红斑狼疮(SLE)患者外周血单个核细胞(PBMC)的表达水平,探讨BCMA在SLE发病中的意义。 方法 纳入2006年1-11月收治的36例SLE患者,同期17例健康志愿者作为对照组,采用半定量RT-PCR法检测外周血单个核细胞中BCMA mRNA的表达,并与SLE疾病活动指数(SLEDAI)进行相关性分析。 结果 SLE患者组BCMA mRNA表达水平(0.598±0.230)均明显高于正常对照组(0.411±0.309)(Plt;0.05)。SLE患者BCMA mRNA表达水平与SLEDAI评分无相关性(P=0.590)。 结论 SLE患者BCMA mRNA表达水平的增高,可能在SLE的发病机制中具有一定的作用。【Abstract】 Objective To detect the mRNA expression of B-cell maturation antigen (BCMA) in peripheral blood mononuclear cells (PBMC) in patients with systemic lupus erythematosus (SLE), and explore the role of BCMA in the pathogenesis of SLE. Methods From January 2006 to November 2006 the expression of BCMA mRNA in PBMC of 36 patients with SLE and 17 normal controls were measured by half-quantitative RT-PCR. The linear correlation between the expression of BCMA mRNA and SLE disease activity index (SLEDAI) was assessed. Results The level of BCMA mRNA (0.598±0.230) in PBMC significantly increased in SLE patients compared with that in the normal controls (0.411±0.309) (Plt;0.05). The expression of BCMA mRNA in SLE patients showed no correlation with SLEDAI score (P=0.590). Conclusion The results suggest that the expression of BCMA mRNA might play an important role in the pathogenesis of SLE.